ODYS vs SGHT vs GKOS vs MVIS

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus -74. 3% for MicroVision, Inc. (MVIS). Analysts rate Odysight. ai Inc. (ODYS) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -95. 2% for MicroVision, Inc. (MVIS). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus SGHT's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Odysight.

ai Inc. (ODYS) is the lower-risk stock at -0. 11β versus MicroVision, Inc. 's 2. 66β — meaning MVIS is approximately -2461% more volatile than ODYS relative to the S&P 500. On balance sheet safety, Odysight. ai Inc. (ODYS) carries a lower debt/equity ratio of 3% versus 66% for MicroVision, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus -74. 3% for MicroVision, Inc. (MVIS). On earnings-per-share growth, the picture is similar: Sight Sciences, Inc. grew EPS 28. 2% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, ODYS leads at 65. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Odysight.

ai Inc. (ODYS) is the more profitable company, earning 36. 5% net margin versus -78. 6% for MicroVision, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GKOS leads at -17. 1% versus -57. 4% for MVIS. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Odysight.

ai Inc. (ODYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ODYS: -38. 1%, SGHT: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ODYS (Technology) and SGHT (Healthcare) and GKOS (Healthcare) and MVIS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ODYS is a small-cap quality compounder stock; SGHT is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; MVIS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.